(1.2) • After prior chemotherapy as a single-agent. (1.3) • Mesothelioma: in combination with cisplatin. (1.4) Limitations of Use: • ALIMTA is not indicated for the treatment of patients with squamous cell non-small cell lung cancer. (1.5) ----------------------- DOSAGE AND ADMINIST RATION ---------------------- • Combination use in Non-Small Cell Lung Cancer and Mesothelioma: Recommended dose of ALIMTA is 500 mg/m2i.v. on Day 1 of each 21-day cycle in combination with cisplatin 75 mg/m2i.v. beginning 30 minutes after ALIMTA administration. (2.1) • Single-Agent use in Non-Small Cell Lung Cancer: Recommended dose of ALIMTA is 500 mg/m2i.v. on Day 1 of each 21-day cycle.